JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.62
−20.59%Oct 21, 2026, 13:00 UTC
Jaguar Health announced that its family company Napo Pharmaceuticals, Inc. has provided crofelemer to an infant with a GUCY2C mutation for several weeks, with treatment reportedly reducing daily and weekly parenteral support needs and being well tolerated.
Source:Oct 13, 2026, 13:00 UTC
Jaguar Health reminded shareholders that October 13, 2026, is the record date for its previously declared special stock dividend to holders of common stock and certain outstanding warrants.
Oct 6, 2026, 13:00 UTC
Napo Pharmaceuticals, a Jaguar Health family company, is sponsoring the 2nd Best of Elite Ped-GI meeting in Abu Dhabi and a panel discussion on intestinal barrier beyond total parenteral nutrition scheduled for October 30, 2026.
Source:Oct 3, 2026, 00:35 UTC
Jaguar Health's Board of Directors declared a special stock dividend of Series R Convertible Preferred Stock to holders of Jaguar common stock and certain outstanding warrants as of the October 13, 2026 record date.
Source:Sep 28, 2026, 11:02 UTC
Jaguar Health, Inc. issued 481,584 shares of common stock to Streeterville Capital, LLC in exchange for a $3,400,000 reduction of its outstanding secured promissory note balance.
Sep 25, 2026, 14:09 UTC
Jaguar Health Inc. announced additional debt-for-equity exchanges that reduced its outstanding debt by over $6.7 million and retired a major promissory note.
Source:Sep 24, 2026, 10:12 UTC
Jaguar Health, Inc. issued 547,898 shares of common stock to Streeterville Capital, LLC in exchange for the surrender of a partitioned secured promissory note with $10,810,000 principal, valued at $5,049,909.26, under a debt-for-equity exchange.
Source:Sep 22, 2026, 13:05 UTC
The U.S. Food and Drug Administration granted Napo Pharmaceuticals a waiver of the PDUFA fee for Mytesi (crofelemer delayed-release tablets) for fiscal year 2027.
Source:Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. agreed to issue 535,000 shares of common stock and a pre-funded warrant for 2,077,255 shares to Joshua Mailman in exchange for all of his shares of Napo Therapeutics S.p.A., closing on September 15, 2026.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 31,847 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 0.4 shares of Series Q Perpetual Preferred Stock.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 219,435 shares of common stock to Streeterville Capital, LLC in exchange for cancellation of 2.8 shares of Series Q Perpetual Preferred Stock.
Sep 15, 2026, 17:46 UTC
Jaguar Health, Inc. issued 557,377 shares of common stock to Lincoln Alternative Strategies LLC in exchange for cancellation of the $175,016.36 outstanding balance on a 6% convertible promissory note.
Sep 15, 2026, 13:00 UTC
Jaguar Health, Inc. announced a 1-for-15 reverse stock split of its common stock, effective September 17, 2026, to support compliance with Nasdaq listing standards.
Source:Aug 5, 2026, 13:00 UTC
Jaguar Health satisfied the conditions to receive a $2 million holdback payment from Future Pak under its U.S. commercial licensing agreement for Mytesi and Canalevia-CA1.
Source: